Trial | NCT03245658  Report issue

Title

The Effect of Cannabis in Pancreatic Cancer
The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Study Started
Oct 06
2017
Anticipated
Primary Completion
May 06
2018
Anticipated
Study Completion
Oct 06
2018
Anticipated
Last Update
Dec 18
2023

Drug THC and CBD Mixture [cannabidiol (Epidiolex), tetrahydrocannabinol]

Individually titrated doses on daily basis

  • Other names: Medical cannabis oral drops

THC and CBD Mixture Experimental

32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks

Control No Intervention

32 patients with palliative pancreatic cancer, no experimental treatment,

Criteria 

Inclusion Criteria:

Adult, palliative pancreatic cancer diagnosis, weight loss > 5%, understand and read Danish.

Exclusion Criteria:

Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy < 6 months
No Results Posted